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Patient 2. A 42-year-old man was referred to a department
of respiratory medicine because of persistent cough, anorexia,
and asthenia. He was a heavy smoker but had no pertinent
medical history and was taking no medication. His temperature
was 38C, and his blood pressure was 110/70 mm Hg. He had
lost 5 kg over the previous two months, and he weighed 46 kg.
Physical examination was normal. Hemoglobin was 10.5 g/dL.
The white blood cell count was 12,000/mm3, with 80% polymor-
phonuclear leukocytes, 1% eosinophils, 10% lymphocytes, and
9% monocytes. The serum creatinine was 55mol/L (0.6 mg/dL);
and blood urea was 2 mmol/L. Liver function tests were normal.
Tests for HIV infection were negative. A chest radiograph was
suggestive of pulmonary tuberculosis, and this diagnosis was
confirmed by the identification of numerous acid-fast bacilli in
sputum smears. The patient was given rifampicin (600 mg/CASE PRESENTATIONS
day), isoniazid (250 mg/day), and pyrazinamide (1500 mg/day).
Patient 1. A 68-year-old man was referred to another hospi- Three weeks later, he had gained 3 kg and was feeling less
tal because of fever and a cutaneous infection of the right elbow. tired. Routine laboratory tests were unchanged; in particular,
On admission, his temperature was 39.5C; heart rate, 120 the serum creatinine was still 55mol/L (0.6 mg/dL). Four weeks
beats/min; and blood pressure, 110/75 mm Hg. The hemoglobin
later, the patient had gained two more kg and his general statuswas 15 g/dL. The white blood cell count was 20,000/mm3, with
seemed to be improving, but laboratory tests showed that the88% polymorphonuclear leukocytes, 7% lymphocytes, and 5%
serum creatinine was 150 mol/L (1.7 mg/dL) and the bloodmonocytes. Serum creatinine was 80 mol/L (0.9 mg/dL), and
urea 10 mmol/L. The patient was referred to our renal unit.blood urea was 5 mmol/L. Seven blood cultures were positive
On admission, he had no complaints. His blood pressure wasfor Staphylococcus aureus, and treatment with methicillin (12 g/
105/70 mm Hg; heart rate, 80 beats/min; and temperature, 37C.day) was initiated. After 12 days of treatment, the fever re-
Physical examination was normal. The serum creatinine wassumed, his renal function deteriorated, and he was transferred
200 mol/L (2.4 mg/dL), and blood urea was 12 mmol/L. Uri-to the renal unit of Hoˆpital Tenon.
nalysis revealed less than one white blood cell/mm3, and lessOn admission, his temperature was 39C. The physical exam-
ination was normal except for the cutaneous lesion of the right than one red blood cell/mm3. Proteinuria was 0.5 g/day. A stain
elbow. The serum creatinine was 320 mol/L (3.6 mg/dL); blood for urinary eosinophils was negative. Hemoglobin was 11 g/dL,
urea was 27 mmol/L. Urinalysis disclosed macroscopic hematu- and the white blood cell count was 10,700/mm3, with 72%
ria and 200 white cells/mm3. Proteinuria was 1 g/day. The white polymorphonuclear leukocytes, 7% eosinophils, 12% lympho-
blood cell count was 12,000/mm3, with 12% eosinophils. Renal cytes, and 9% monocytes. Eosinophilia subsequently increased
biopsy disclosed an infiltration of the interstitium by numerous to 1,000/mm3. Renal sonography was normal. Rifampicin ad-
lymphocytes and macrophages that was associated with severe ministration was stopped. Renal biopsy disclosed extensive
tubular lesions. Glomeruli and blood vessels were normal. Im-
inflammatory infiltrates within the interstitium that were com-munofluorescent studies showed linear deposits of IgG along
posed of lymphocytes and macrophages; granulomas were notthe tubular basement membranes. Methicillin was replaced
seen. The inflammatory infiltrates were associated with intersti-by pristinamycin. Hematuria, pyuria, and proteinuria quickly
tial edema, focal tubular lesions ranging from mild to severe,resolved, and his renal function progressively returned to base-
and in some places slight fibrosis. All 22 glomeruli were normal.line values.
Immunofluorescent examination of the biopsy specimen re-
vealed no immune deposits. No anti-rifampicin antibody could
be detected. After stopping rifampicin, his renal function pro-The Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co., Incorporated; and Dialysis Clinic, Incorpo- gressively improved, but two years after this episode, the serum
rated. creatinine remains 130 mol/L (1.5 mg/dL), which corresponds
to a calculated creatinine clearance of 50 mL/min. 2001 by the International Society of Nephrology
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DISCUSSION the immunogenicity of native renal proteins (Fig. 1A),
or it could mimic renal antigens and induce an immuneDr. Je´roˆme Rossert (Department of Nephrology and
reaction that also will be directed against componentsINSERM U489, Hoˆpital Tenon; and Professor of Nephrol-
of the TBM (Fig. 1B).ogy, University of Paris VI, Paris, France): The two pa-
Experimental AIN also can be induced by promotingtients presented today, but who were seen more than 20
immune reactions against extrarenal proteins that haveyears apart, both had acute interstitial nephritis (AIN).
become trapped within the kidney (“planted” antigen).Acute interstitial nephritis is a rather uncommon disease
The lesion can be induced by injecting rabbits daily withthat has occurred at a relatively stable rate over the years.
bovine serum albumin, or by injecting aggregated bovineIn three large series published between 1988 and 1998,
gamma globulins under the renal capsule of pre-sensi-AIN represented 2% to 3% of all renal biopsies [1–3].
tized rats or guinea pigs [reviewed in 4]. In the formerNevertheless, the clinical presentation of drug-induced
case, the AIN is associated with a glomerulonephritis andAIN has changed since the time when methicillin-induced
is characterized by granular deposits of immunoglobulins,AIN was prototypical of this entity. After briefly dis-
C3, and antigen along the TBM, in the interstitium, andcussing the pathophysiology of drug-induced AIN, and
in the basal area of interstitial capillaries. In the latterin particular the links between AIN and interstitial fi-
case, aggregated bovine gamma globulins induce delayed-brosis, I will review the clinical spectrum of drug-induced
type hypersensitivity reactions within the interstitium.AIN, the diagnostic tools that can be used besides renal
These two animal models could correspond to humanbiopsy, and the prognosis and treatment of this disease.
AIN induced by drugs that trigger an immune reaction
and become deposited within the interstitium. The drugPathophysiology
could first be trapped in the interstitium and then becomeFour arguments strongly suggest that drug-induced
the target of an immune reaction, as exemplified by theAIN is secondary to immune reactions in humans. First,
second model (Fig. 1C). It could also form circulatingAIN occurs only in a small percentage of individuals
immune complexes, which then deposit in the intersti-
taking the drug. Second, AIN is not dose-dependent.
tium, as might be the case in the first model (Fig. 1D).
Third, drug-induced AIN is associated with extrarenal Studies of experimental models of AIN have shown
manifestations of hypersensitivity. Four, AIN usually re- that their induction can involve either cell-mediated im-
curs after accidental re-exposure to the drug or to a munity or antibody-mediated immunity, and that in some
closely related agent. It is thus tempting to draw a parallel cases the same antigen can even trigger either type of
between drug-induced AIN and immune-mediated ex- immune response depending on the species [reviewed
perimental AIN, and to use these experimental models in 4, 5]. For example, immunization of strain XIII guinea
to understand the pathophysiology of drug-induced AIN. pigs with heterologous TBM induces an AIN associated
Two main categories of antigens can induce experi- with linear deposits of IgG along the TBM and mediated
mental AIN: (1) endogenous renal antigens, which can by antibodies. The lesion can be transferred with anti-
be either non-collagenous components of the tubular bodies but not with immune cells, and guinea pigs are
basement membrane (TBM) or proteins synthesized by protected from the disease by “decomplementation” or
tubular cells but which are not part of the TBM, and (2) by injection of anti-idiotypic antibodies [7–9]. In con-
non-renal antigens [reviewed in 4, 5]. The ability of renal trast, immunization of SJL mice with heterologous TBM
antigens to induce AIN has been extensively studied induces a purely cell-mediated AIN. This AIN can be
since the first description of this model in 1971 [6]. Immu- induced by injection of a T-cell clone that mediates de-
nization of some strains of guinea pigs (such as strain layed-type hypersensitivity but it cannot be transferred
XIII), of rats (such as Brown-Norway rats), or of mice by anti-TBM antibodies [10, 11].
(such as SJL mice) with heterologous TBM can induce In humans, most drug-induced AIN probably involves
AIN [reviewed in 4, 5]. Similarly, animals immunized cell-mediated immunity, as renal biopsies usually do not
with endogenous renal proteins that are not part of the disclose any immune deposits. This hypothesis is re-
TBM can develop AIN. Immunization of rabbits or rats inforced by the fact that interstitial infiltrates usually con-
with Tamm-Horsfall protein, or injection of rats with tain a considerable percentage of T-cells and that they
antisera to Tamm-Horsfall protein can induce AIN [re- sometimes form granulomas. Nevertheless, deposition
viewed in 4]. Immunization of Lewis rats with megalin of anti-TBM antibodies or immune complexes can be
induces a membranous nephropathy, which has been observed occasionally on renal biopsies, as in the methi-
associated with tubular lesions and interstitial inflamma- cillin-induced AIN in today’s first patient. In these cases,
tory infiltrates [reviewed in 4]. These models suggest that antibody-mediated immunity might play a role in the
drugs responsible for AIN induce an immune reaction induction of the disease.
directed against endogenous renal antigens. The drug or Analyses of human renal biopsy tissue and of kidneys
taken from animals with experimental AIN have shownone of its metabolites could serve as a hapten and modify
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Fig. 1. Mechanisms whereby a drug (or one
of its metabolites) can induce acute interstitial
nephritis (AIN). (A) The drug can bind to a
normal component of the tubular basement
membrane (TBM) and act as a hapten. (B) The
drug can mimic an antigen normally present
within the TBM or the interstitium and induce
an immune response that will also be directed
against this antigen. (C) The drug can bind to
the TBM or deposit within the interstitium
and act as a planted (“trapped”) antigen. (D)
The drug can elicit the production of antibod-
ies and become deposited in the interstitium
as circulating immune complexes.
that acute interstitial inflammatory reactions are associ- tion of extracellular matrix by these cells in vitro [re-
viewed in 2, 18]. For example, inflammatory cells canated with damage to tubular cells. These tubular lesions
probably play a key role in the pathogenesis of acute produce transforming growth factor- (TGF-), inter-
leukin (IL)-1, IL-4, and lipid peroxidation products,renal failure associated with AIN. The lesions are multi-
factorial and are due to direct interactions between in- which increase the production of extracellular matrix
proteins by fibroblastic cells in vitro. Similarly, tubularflammatory cells and tubular epithelial cells, to the re-
lease of soluble molecules by inflammatory cells, or to cells can synthesize TGF-, insulin-like growth factor-1
(IGF-1), endothelin-1 (ET-1), and lipid peroxidationactivation of the complement cascade. Nevertheless, tu-
bular cells are not only a target for inflammatory lesions, products, which stimulate the production of extracellular
matrix components by fibroblastic cells in vitro. Never-they also can actively interact with infiltrating cells to
increase interstitial inflammation. Analyses of renal bi- theless, in vivo only three of these molecules induce
fibrotic reactions within the renal interstitium: TGF-,opsies, studies of kidneys from animals with experimen-
tal nephritides, and co-culture experiments have shown ET-1, and platelet-derived growth factor-BB (PDGF-BB).
A potent anti-inflammatory molecule, TGF-1 isthat in response to an insult tubular cells can become
activated and produce pro-inflammatory molecules such probably the most important profibrotic factor identified
so far. It is produced by many cells, including monocytes/as cytokines, growth factors, adhesion molecules, or che-
mokines [reviewed in 12, 13]. For example, analyses of macrophages, lymphocytes, fibroblasts, endothelial cells,
and tubular cells. After being activated, TGF-1 bindsrenal biopsies from patients with AIN or from Brown-
Norway rats immunized with heterologous TBM have to its receptors and acts mostly by inducing the phosphor-
ylation of Smad proteins [reviewed in 19]. The profibroticdisclosed an overexpression of chemokines by tubular
cells [14, 15], and co-culture experiments have shown properties of TGF-1 are explained by its ability to be
chemotactic for fibroblasts, to induce a proliferation ofthat, in vitro, T-cells can induce chemokine production
by tubular epithelial cells [16]. Similarly, in a mouse fibroblastic cells, to increase the transcription of genes
encoding proteins of the extracellular matrix and the sta-model of spontaneous acute interstitial nephritis, tubular
cells overexpress the osteopontin gene, which encodes bility of the corresponding mRNAs, to inhibit the pro-
duction of metalloproteinases, and to increase the pro-an adhesion molecule [17].
In some cases, acute interstitial inflammatory reactions duction of tissue inhibitors of metalloproteinases (TIMPs),
which are their natural inhibitors [reviewed in 20]. Never-induce an accumulation of extracellular matrix that leads
to permanent impairment of renal function. Experimen- theless, some of these profibrotic properties might be indi-
rect and mediated by increased production of a cysteine-tal studies and analyses of renal biopsies have shown
that macrophages, lymphocytes, and activated tubular rich protein called connective tissue growth factor [21].
The ability of TGF-1 to induce renal interstitial fibrosiscells can produce many cytokines that can induce a pro-
liferation of fibroblastic cells, and/or increase the produc- has been shown by an analysis of the phenotype of trans-
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genic mice, which produce high levels of active TGF-1. tensin II on extracellular matrix production are indirect,
mediated through an increased production of growthTransgenic mice, which express a cDNA encoding ma-
ture TGF-1 under the control of the albumin enhancer/ factors such as TGF- or PDGF, and of other molecules
such as thrombospondin-l [reviewed in 35].promoter, have elevated circulating levels of TGF-1,
and progressively develop fibrosis of different organs,
Clinical presentationincluding liver and kidney [22]. Analysis of the corre-
sponding kidneys shows that they display glomerular Methicillin-induced AIN has long been considered
prototypical of drug-induced AIN. About 100 cases ofimmune deposits, glomerulosclerosis, and interstitial fi-
brosis [23]. Similarly, transgenic mice that harbor a cDNA methicillin-induced AIN have been described in the En-
glish literature, and analysis of these case reports showsencoding active TGF-1 under the control of rat phos-
phoenolpyruvate carboxykinase regulatory sequences de- that the corresponding clinical picture was quite mono-
morphic (Fig. 2) [reviewed in 36–38]. Renal symptomsvelop renal interstitial fibrosis, glomerulosclerosis, and
fibrosis of the liver and adipose tissue [24]. typically developed about two weeks after the patients
started taking methicillin. Hematuria was present in 90%In vivo, ET-1 also can induce renal interstitial fibrosis.
The predominant isoform of endothelin, ET-1 is pro- of cases. It was macroscopic in about 80% of cases and
was never associated with red blood cell casts. Pyuriaduced by endothelial cells, vascular smooth muscle cells,
and tubular cells [reviewed in 25]. Its production can was almost always present and often was associated with
leukocyte casts. Renal failure, which occurred in onlybe induced by a variety of stimuli, including hypoxia,
angiotensin II, and TGF-. In vivo, the profibrotic prop- 50% of adults and 15% of children, was oliguric in 20%
of the cases. Approximately 33% of the patients witherties of endothelin have been demonstrated by the anal-
ysis of transgenic animals overexpressing either ET-1 or abnormal renal function required dialysis. The most
common extrarenal symptom was fever, which was pres-ET-2, and by the beneficial effects of endothelin inhibi-
tors in various experimental models of fibrosis involving ent in about 80% of patients, could be as high as 40C,
and usually lasted 7 to 10 days after discontinuation oforgans such as kidney, liver, or lung. For example,
Hocher et al generated transgenic mice using a 16 kb methicillin. A generalized cutaneous rash was observed
in only 25% of patients, and arthralgias were uncommon.fragment of human genomic DNA that contained the
ET-1 gene, about 8 kb of 5 flanking sequence, and 1.5 Eosinophilia was present in about 80% of patients, rang-
ing from 500 to 5000/mm3. After the methicillin was dis-kb of 3 flanking sequence [26]. These mice overexpress
ET-1 predominantly in lung, brain, and kidney, are nor- continued, hematuria and pyuria usually resolved within
a few days, but renal failure, when present, could last muchmotensive, and progressively develop glomerulosclero-
sis, renal interstitial fibrosis, and pulmonary fibrosis longer and its mean duration was 1.5 months. Neverthe-
less, complete recovery of renal function was the rule,[26, 27]. Although few in vitro studies are available to
explain the profibrotic properties of ET-1, this molecule and serum creatinine returned to normal levels in about
90% of reported patients.has been shown to be mitogenic and to stimulate collagen
synthesis by some fibroblastic cell lines, as well as by Besides methicillin, many other drugs can induce AIN
(Table 1), but the clinical presentation of AIN inducedvascular smooth muscle cells, hepatic stellate cells, and
osteoblastic cells [28–32]. Nevertheless, ET-1’s mode of by these drugs is often incomplete and less suggestive
of the diagnosis, as illustrated by the second patientaction is still elusive. In particular, the mechanism of its
ability to directly modulate the transcription of collagen presented today. To try to get a global view of this entity,
we reviewed more than 150 case reports, as well as ourgenes and/or the stability of the corresponding mRNAs
remains unknown. own unpublished cases (Fig. 2). This analysis showed
that renal manifestations develop within three weeksThe third molecule that induces fibrosis in the renal
interstitium, PDGF-BB, is a potent growth factor. It after starting the inciting drug in about 80% of patients,
with an average delay of about ten days. The clinicalinduces renal interstitial fibrosis in vivo: continuous infu-
sion of PDGF-BB to rats induces not only a proliferation presentation most suggestive of the diagnosis is that of
a sudden impairment of renal function associated withof interstitial myofibroblastic cells, but also an accumula-
tion of extracellular matrix within the renal interstitium mild proteinuria and abnormal urinalysis in a patient
with flank pain, normal blood pressure, and no edema.[33]. Nevertheless, the profibrotic effects of PDGF-BB
are probably indirect and mediated by an overproduc- Nevertheless, such a clinical picture is observed in less
than one-fourth of cases. Analysis of the different mani-tion of TGF-1 [34].
In recent years, much attention has focused on angio- festations showed that renal failure is almost constant,
and that dialysis is required in about one-half of patients.tensin II as a profibrotic molecule, because of beneficial
effects of angiotensin I converting enzyme inhibitors on The presentation is usually that of parenchymal renal
failure, but patients with a low fractional excretion ofthe progression of chronic renal diseases [reviewed in
35]. Nevertheless, data suggest that the effects of angio- sodium occasionally have been reported. Hematuria and
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Fig. 2. Approximated frequency with which clinical manifestations occur during the course of methicillin-induced AIN (A), AIN induced by drugs
other than methicillin (B), or AIN induced by NSAIDs and associated with a nephrotic syndrome (C). Proteinuria was considered positive when
it was at least 0.5 g/L or  by dipstick. Data are derived from case reports and from analysis of our own cases.
pyuria are each present in only about 50% of patients. for a few months (mean delay, 6 months). Furthermore,
AIN induced by NSAID and associated with a nephroticFlank pain, reflecting distension of the renal capsule, is
also observed in about the same percentage of cases, syndrome usually occurs in patients over 50, possibly
because NSAIDs are consumed more often by elderlyand it can be the main complaint on admission. Ultra-
sonography usually discloses an increased cortical echo- people. Besides these particularities, the presentation is
quite similar to that of other types of drug-induced AINgenicity (comparable to or higher than that of the liver),
but as far as we know, the diagnostic value of this finding (Fig. 2). The main differences are that hematuria is al-
most never macroscopic and extrarenal symptoms arehas not been assessed [39]. Extrarenal symptoms and
signs reflecting a hypersensitivity reaction typically in- present in only about 10% of these patients.
Not all NSAIDs have the same propensity to induceclude low-grade fever, maculopapular rash, mild arthral-
gias, and eosinophilia, but each of these manifestations a nephrotic syndrome. Fenoprofen accounts for almost
50% of the reported cases, and other NSAIDs have onlyis present in fewer than 50% of patients, and all of them
are present together in fewer than 5% of patients. With been involved in a few cases. Besides NSAIDs, a few
cases of AIN associated with a nephrotic syndrome havesome drugs, such as rifampicin or allopurinol, other man-
ifestations of hypersensitivity such as hemolysis or hepa- been reported after administration of ampicillin, rifampi-
cin, lithium, interferon, diphenylhydantoin, or D-penicil-titis can be present. Nevertheless, it should be empha-
sized that signs of hypersensitivity are not specific to lamine [41–45].
The association between rifampicin administration andAIN and they also can be observed in patients with acute
renal failure not related to AIN. In a study of 81 patients AIN is common; more than 100 patients with rifampicin-
induced AIN have been reported [reviewed in 46, 47].with acute renal failure who had a renal biopsy, signs of
hypersensitivity were found in 14% of patients with drug- Analysis of these cases shows that they fall into two quite
different categories, patients treated over the short terminduced acute tubular necrosis [40].The clinical and bio-
logic manifestations of AIN might have some specificity, with rifampicin, and those whose AIN occurs subsequent
to intermittent or earlier use of the drug.depending on the drug involved, and I would like to
emphasize the particularities of AIN induced by nonste- In five reported cases [46], and in today’s second pa-
tient, AIN developed in patients who had been continu-roidal anti-inflammatory drugs (NSAIDs) and by rifam-
picin. Analysis of more than 80 case reports showed ously treated with rifampin for one to ten weeks. The
patients had mild to severe acute renal failure, and twothat NSAID-induced AIN is associated with a nephrotic
syndrome in more than 70% of patients and that it usu- patients had nephrotic-range proteinuria. Extrarenal
symptoms were present in only one patient. In all cases,ally is diagnosed in patients who have taken the drug
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Table 1. Drugs responsible for acute interstitial nephritis (AIN)
Antimicrobial agents NSAIDs including salicylates Diuretics
Acyclovir Alclofenac Chlorthalidone
AMPICILLINab Azapropazone Ethacrynic acid
Amoxicillin ASPIRIN FUROSEMIDEb
Aztreonam Benoxaprofen Hydrochlorothiazideb
Carbenicillin Diclofenac Indapamide
Cefaclor Diflunisalb Tienilic acidb
Cefamandole Fenclofenac Triamtereneb
Cefazolin FENOPROFEN
Cephalexin Flurbiprofen Others
Cephaloridine IBUPROFEN
Cephalothin INDOMETHACIN
Cephapirin Ketoprofen ALLOPURINOLb
Cephradine Mefenamic acid Alpha-methyldopa
Cefixitin Meloxicam Azathioprine
Cefotetan Mesalazine (5-ASA) Bethanidineb
Cefotaxime NAPROXEN Bismuth salts
CIPROFLOXACIN Niflumic acid Captoprilb
Cloxacillin Phenazone Carbimazoleb
Colistin PHENYLBUTAZONE Chlorpropamideb
Cotrimoxazoleb PIROXICAM Cyclosporine
Erythromycin Pirprofen CIMETIDINE
Ethambutol Sulfasalazine Clofibrate
Foscarnet Sulindac Clozapine
Gentamicin Suprofen Cyamethazineb
Indinavir TOLEMETIN D-penicillamine
Interferon ZOMEPIRAC Fenofibrateb
Isoniazid Gold salts
Lincomycin Analgesics Griseofulvin
METHICILLINb Interferon
Mezlocillin Interleukin-2
Minocycline Aminopyrine OMEPRAZOLE
Nafcillin Antipyrine PHENINDIONEb
Nitrofurantoinb Antrafenin Phenothiazine
Norfloxacin Clometacin
b
Phenylpropanolamine
Oxacillinb Floctafenin
b
Probenecid
PENICILLIN Gb Glafenin
b
Propranolol
Piperacillin Metamizol Propylthiouracil
Piromidic acid Noramidopyrine Ranitidine
Polymyxin acidb Streptokinase
Quinine Anticonvulsants Sulphinpyrazone
RIFAMPICINb Warfarin
Spiramycineb Carbamazepine
SULFONAMIDES Diazepam
Teicoplanin Phenobarbital
Tetracycline PHENYTOINb
Vancomycin Valproate sodium
a Drugs most commonly involved are shown in capital letters
b Drugs that can induce granulomatous AIN
renal biopsy disclosed severe interstitial inflammatory tients, and anti-rifampicin antibodies are present in most
cases. Renal biopsy usually shows substantial tubularinfiltrates with a few tubular lesions. No patient had anti-
rifampicin antibody. Renal function completely recov- lesions in addition to inflammatory infiltrates, but immu-
nofluorescence staining does not reveal immune depos-ered in four patients after discontinuing the drug, but
its. This pattern suggests that anti-rifampicin antibodiesin two patients, the serum creatinine did not return to
are not responsible for the renal lesions and that cell-baseline values.
mediated immunity plays a key role in the induction ofThe vast majority of cases of rifampicin-induced AIN
this nephropathy.comprise patients receiving intermittent therapy or pa-
tients previously exposed to the drug [46, 47]. In these
Noninvasive diagnostic proceduresinstances, symptoms occur abruptly and usually are ac-
companied by fever, chills, digestive manifestations (nau- The clinical diagnosis of drug-induced AIN is quite
often difficult. Two diagnostic procedures have been pro-sea, vomiting, diarrhea, abdominal pain), flank pain, and
myalgias. Laboratory tests disclose thrombocytopenia posed to allow an accurate diagnosis without performing
a renal biopsy: determination of eosinophiluria and gal-and hemolysis in about one-fourth to one-third of pa-
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Table 2. Diagnostic value of eosinophiluria uptake of 67Ga in patients with AIN, but as far as we
know, only one large series has been reported [55]. InNumber of patients 65 92 183 199 539
this study, 44 patients with biopsy-proven renal disease,Patients with AIN
Eosinophiluria 8 10 5 6 29 18 patients with clinically diagnosed renal disease, and 46
No eosinophiluria 1 1 3 9 14 patients without renal disease had renal gallium scanning.
Patients without AIN
All 11 patients with biopsy-proven AIN had an intenseEosinophiluria 27 12 15 10 64
No eosinophiluria 29 69 160 174 432 renal 67Ga uptake at 48 hours, but 9 patients without
AIN also had positive renal scanning. These patients hadReference [48] [49] [50] [51] [48–51]
glomerulonephritis, pyelonephritis, chronic interstitial
nephritis, or even no renal disease. Thus, from this series,
renal scanning appears to be a very sensitive method for
identifying AIN but to have a lower specificity. Neverthe-lium scanning. Galpin et al reported that at least 10%
of urinary white cells were eosinophils in nine patients less, the sensitivity of gallium scanning has been chal-
lenged by at least two groups. In a small series of 16with methicillin-induced AIN, and this was not the case
in 43 patients with renal diseases different from AIN [38]. patients with acute renal failure and drug-induced AIN,
only 11 (69%) had positive gallium scanning [56]. InThus, measuring the percentage of eosinophils among
urinary white cells could be helpful in making the diagno- another small series of 12 patients with interstitial ne-
phritis, only 7 (58%) had positive renal 67Ga scanning,sis of AIN. Two stains have been used to detect urinary
eosinophils: the classic Wright’s stain and Hansel’s stain, but in this series patients with a negative scan probably
had a chronic interstitial nephritis rather than AIN, andwhich are both eosin-methylene blue combinations. The
latter appears to be much more sensitive, and in two none of them had drug-induced renal disease [57]. The
relative lack of specificity of gallium scanning is supportedseries including a total of 19 patients with AIN, eosino-
philuria was demonstrated by Hansel’s stain in 15 pa- by case reports describing patients with renal uptake of
67Ga who had diseases such as cancer, pyelonephritis,tients (79%) and by Wright’s stain in only four patients
(21%) [49, 50]. Eosinophiluria is considered positive minimal change disease, or acute renal failure associated
with IgA nephropathy (personal observations) [55, 58].when more than 1% of white cells are stained.
Four large series have studied the usefulness of eosino- Clinical presentation of AIN being quite polymorphic,
and noninvasive diagnostic procedures having clear limi-philuria for the diagnosis of AIN (Table 2) [48–51]. Be-
cause of the heterogeneity of these series, and because tations, renal biopsy is often essential for the diagnosis.
Its importance has been illustrated by a series of 32 pa-some cases of AIN were not confirmed by a renal biopsy
but only by a retrospective analysis of the patient’s file, tients with acute renal failure [2]. In this series, 7 patients
(22%) had AIN but another diagnosis had been sus-it is difficult to draw a definite conclusion about the use-
fulness of eosinophiluria. Nevertheless, eosinophiluria pected before the biopsy. In contrast, in 25 patients thought
to have AIN, biopsy confirmed the diagnosis in onlyseems to have a rather low sensitivity, and if one consid-
ers all four series, only 29 of 43 patients with AIN (67%) 11 (44%). Let me very briefly review the well known
histologic features of AIN.had eosinophiluria (Table 2). On the other hand, eosino-
philuria could be relatively specific for AIN. Of 436 pa- The hallmark of AIN is the presence of inflammatory
infiltrates within the interstitium. These infiltrative lesionstients without AIN, 372 (85%) had no eosinophiluria
(Table 2), and if only the 210 patients with acute renal can be diffuse, but often they are patchy, predominating
in the deep cortex and in the outer medulla. They arefailure are considered, the specificity of the test is similar,
as 138 patients had no eosinophiluria out of 167 patients composed mostly of T-cells and of monocytes/macro-
phages; plasma cells, eosinophils, and a few neutrophilicnot having AIN (83%). Among patients with eosino-
philuria but no AIN, renal failure can be due to diseases granulocytes also can be present. Among T-cells present
within the interstitium, the relative number of CD4such as acute tubular necrosis, glomerulonephritis, athero-
thromboembolic renal disease, or even pre-renal azote- T-cells and CD8 T-cells appears to be quite variable
from one patient to another [59–63]. The relative repre-mia [48–52]. Furthermore, in the first three series, eosino-
philuria was found in 28% of 93 patients with urinary sentation of T-cells is probably influenced by the noxious
drug, but also by other factors such as the genetic back-tract infection [48–50]. Urinary schistosomiasis is also as-
sociated with eosinophiluria, and in a series of 58 patients ground of the patient. Infiltrating cells sometimes form
granulomas, which are usually sparse, non-necrotic, withwith urinary schistosomiasis, all had eosinophiluria [53].
Wood et al reported two decades ago a marked renal a few giant cells, and associated with non-granulomatous
interstitial infiltrates. In some cases, T-lymphocytes infil-uptake of gallium (67Ga) in three patients with AIN [54]
and suggested that 67Ga renal scanning could be a useful trate across the TBM and between tubular cells, causing
what is known as tubulitis.tool for the diagnosis of AIN. Isolated case reports have
supported this hypothesis by showing a substantial renal Interstitial infiltrates are always associated with an
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interstitial edema separating the tubules. They also can the severity of tubulitis is not predictive of the outcome
[63]. In this last series, as in a larger one [66], the mainoccur with focal tubular lesions, which range from mild
cellular alterations to extensive necrosis of epithelial cells, prognostic factor was the severity of the interstitial fi-
brosis, but this factor was not of prognostic value in aand which sometimes disrupt the TBM. These tubular
lesions usually predominate where the inflammatory in- third series of 10 patients [62]. It is possible that these
discrepancies regarding the prognostic value of histologicfiltrates are most extensive. Vessels and glomeruli appear
normal, and even in AIN associated with a nephrotic lesions arise from the fact that renal biopsies were per-
formed at different times after the onset of AIN.syndrome, the structure of the glomeruli is preserved on
light microscopy, and only on electron microscopy can The best prognostic factors might be the duration of
acute renal failure and/or renal function a few weeksfusion of foot processes be seen.
In the vast majority of cases, renal biopsies from pa- after the diagnosis. In a series of 30 patients, mean serum
creatinine values at the end of follow-up were about 120tients with AIN do not show immune deposits. Neverthe-
less, linear staining of the TBM for IgG occasionally can mol/L (1.4 mg/dL) when acute renal failure lasted less
than two weeks, and about 300mol/L (3.4 mg/dL) whenbe seen, mostly in patients taking methicillin, an NSAID,
phenylhydantoin, or allopurinol. Immune deposits indi- it lasted more than three weeks [64]. In another series
of 14 patients, serum creatinine values at the end ofcate the presence of antibodies directed against membrane
antigens or against drug metabolites bound to the TBM. follow-up closely correlated with renal function 6 to 8
weeks after the diagnosis [65].
Course and treatment Removing the drug responsible for AIN is probably
the most important aspect of treatment, and administra-Based on the course of methicillin-induced AIN, drug-
induced AIN has long been considered a relatively be- tion of the inciting agent should be stopped as soon as
possible. The possibility that AIN evolves toward chronicnign nephropathy, and complete recovery of renal func-
tion was supposed to be the rule if the inciting agent was renal failure prompted different researchers to treat pa-
tients not only by removing the inciting drug, but alsoremoved. Nevertheless, even in the case of methicillin-
induced AIN, although hematuria, leukocyturia, and ex- by administering a brief course of corticosteroids. Thera-
peutic regimens have been variable, but most patientstrarenal manifestations usually disappeared within two
weeks, complete recovery of renal function often was received an initial dose of 1 mg/kg/day prednis(ol)one,
which was then tapered over a few weeks. Analysis ofdelayed, with a mean recovery time of about 1.5 months.
Analysis of published cases of AIN induced by drugs other seven series comparing patients who received corticoste-
roids with others who did not indicated that corticoste-than methicillin and review of our own cases show that
nowadays the course of drug-induced AIN is far from roids did not decrease the risk of chronic renal failure
[2, 38, 56, 66–69]. In 52 patients who received corticoste-always being benign, and that the serum creatinine level
remains elevated in about 40% of patients (Fig. 3A). roids, serum creatinine levels remained above 200 mol/L
(2.3 mg/dL) in 17% of cases and decreased below 110It would be clinically important if we could identify
patients with drug-induced AIN who are at high risk mol/L (1.3 mg/dL) in only 58%. Similarly, in 48 patients
who did not receive corticosteroids, serum creatinineof incomplete recovery. Unfortunately, few prognostic
factors are available. One could have assumed that the levels remained above 200 mol/L (2.3 mg/dL) in 19%
and decreased below 110mol/L (1.3 mg/dL) in only 52%.severity of renal failure was correlated with the progno-
sis, but analysis of different series suggests that maximal Nevertheless, I should stress that all seven series are
small, non-randomized, and retrospective, and that renalserum creatinine levels have little prognostic value (Fig.
3B). Most histologic data also appear not to predict out- failure tended to be more severe in patients receiving
corticosteroids than in those not treated with corticoste-come. In a series of 30 patients with AIN, renal prognosis
was less favorable when interstitial infiltrates were dif- roids [mean maximum serum creatinine values, 818mol/L
(9.3 mg/dL) vs. 570 mol/L (6.5 mg/dL), respectively].fuse and not patchy; at the end of follow-up, mean serum
creatinine was higher than 175 mol/L (2.0 mg/dL) in In contrast, a brief course of corticosteroids can hasten
the recovery of renal function [2, 69]. For example, in10 of 18 patients with diffuse infiltrates (55%), whereas
it was below 100 mol/L (1.1 mg/dL) in 9 of 12 patients ten patients whose renal function did not improve within
5 to 20 days after the inciting drug was stopped, adminis-with patchy infiltrates (75%) [64]. Nevertheless, in two
other studies including 27 and 14 patients respectively, tration of pulse methylprednisolone for three days or of
prednisolone (40 to 60 mg/day for three to four weeks)no correlation could be established between the extent
of interstitial infiltrates and either the long-term outcome quickly induced a dramatic decrease of serum creatinine
values [2]. One can thus suggest administering a shortor the duration of renal failure [2, 65]. Other authors
have suggested that the presence of granulomas in the course of prednis(ol)one in patients whose renal function
fails to improve within one week after stopping the incit-renal interstitium indicates poor prognosis, but this also
has not been established. A small series suggests that ing drug, provided that the diagnosis of AIN has been
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Fig. 3. Evolution of renal function in patients with drug-induced AIN, as a function of maximum serum creatinine levels. (A) Correlation between
maximum serum creatinine values and serum creatinine values at the end of follow-up. Only 68% and 49% of patients had serum creatinine levels
below 150 mol/L (1.7 mg/dL) and 110 mol/L (1.2 mg/dL) at the end of follow-up, respectively. (B) Patients were arbitrarily divided into three
groups depending on serum creatinine levels at the end of follow-up: patients with serum creatinine below 110 mol/L (1.2 mg/dL); patients with
serum creatinine between 110 and 200 mol/L (1.2 and 2.2 mg/dL), and patients with serum creatinine above 200 mol/L (2.2 mg/dL). Maximum
serum creatinine levels did not differ among these three groups. S, serum.
confirmed by renal biopsy. Our tendency is also to use ecules of the TBM that can function as antigens in tubu-
lointerstitial nephritis. Could you tell us more aboutcorticosteroids in patients whose nephropathy has evolved
for more than two to three weeks. It is of note that in some of them in terms of their structure, expression, and
whether their nephritogenic domains have similarities?patients with NSAID-induced AIN, corticosteroids do
not seem to modify the course of the nephrotic syndrome. Dr. Rossert: Different groups have tried to precisely
identify molecules of the TBM that are recognized byIn conclusion, the clinical spectrum of drug-induced
AIN has largely changed since the time when methicillin anti-TBM antibodies and that can induce AIN. In 1991,
Eric Neilson and colleagues cloned a cDNA encoding awas the most frequent culprit. Clinicians now have to
peptide that is recognized by anti-3M-1 antibodies, thatface two problems. The first is the diagnosis of drug-
is, antibodies recognizing a 48 kD protein involved ininduced AIN in patients with isolated acute renal failure.
the pathogenesis of experimental AIN; this peptide isRenal biopsy remains an essential tool in most cases,
present within cortical TBM and appears to harbor aeven though the presence of eosinophiluria may be help-
major nephritogenic epitope [70], but the proteins con-ful. The second is the prevention of interstitial fibrosis.
taining this peptide are still unknown. In 1992, KazuoCorticosteroids are the only drugs available so far, but
Yoshioka and coworkers purified and partially sequencedthey seem to be more effective in accelerating the recov-
a protein called gp54 [71]. Recognized by sera from pa-ery of renal function than in preventing interstitial fibro-
tients with anti-TBM nephritis, it can induce experimen-sis. In the coming years, a better understanding of the
tal AIN, and it is present selectively in the basementmechanisms responsible for the interstitial infiltration by
membrane of proximal tubules. In 1995, Todd Nelsoninflammatory cells, and for the increased production of
et al cloned a cDNA encoding a third protein, calledextracellular matrix within the interstitium, should help
TIN-Ag/TIN1, which is a 58 kD glycoprotein that is recog-define new therapeutic agents.
nized by sera from patients with anti-TBM AIN [72]. This
protein, which is expressed mainly in the renal cortex,
QUESTIONS AND ANSWERS interacts with type IV collagen and laminin and promotes
Dr. Nicolaos E. Madias (Executive Academic Dean, cell adhesion. Recently, an alternative spliced form of
Tufts University School of Medicine, Boston, Massachu- TIN-Ag, called TIN2, was described in humans [73]. In-
setts, USA): Thank you very much, Dr. Rossert, for a terestingly, the antisera used to characterize TIN-Ag/
TIN1 also can immunoprecipitate 3M-1 and gp54; thiswonderful presentation. You presented a number of mol-
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finding suggests that different nephritogenic proteins are of CTGF induced by TGF-, one possibility would be
to modulate the cellular levels of cyclic AMP [21].present within the TBM and have similar nephritogenic
epitopes. Nevertheless, the peptide cloned by Eric Neil- Dr. John Feehally (Department of Nephrology, Leices-
ter General Hospital, Leicester, UK): How characteristicson and thought to represent a major nephritogenic do-
main of 3M-1 is not present in TIN-Ag/TIN1. are eosinophils in the kidney as a feature of interstitial
infiltrates, and do you believe that they have any specialDr. Madias: You mentioned that in a significant num-
ber of patients, the AIN evolves towards chronicity and role in the pathophysiology of AIN?
Dr. Rossert: Eosinophils can be present within theinterstitial fibrosis. We could probably learn a fair amount
about the mechanisms of this process by studying the interstitial inflammatory infiltrates, but they do not seem
to be characteristic of drug-induced AIN. In a series ofnormal repair process. Can you tell us a little bit about
the biology of repair in AIN? 12 children with AIN, 7 of 8 patients with drug-induced
AIN had renal eosinophilia but 3 of 4 children with AINDr. Rossert: Two different aspects comprise this rep-
aration process: one is the resolution of the interstitial not induced by a drug also had renal eosinophilia [76].
Similarly, eosinophils can be present within interstitialinflammatory reaction, and the other is the repair of the
damaged tubules. Resolution of inflammatory reactions infiltrates during the course of acute rejection. It is tempt-
ing to speculate that the presence of eosinophils is second-is a complex process that is far from being limited to a
decreased production of pro-inflammatory factors. It also ary to an infiltration by TH2 cells and to the production
of cytokines such as IL-5. Regarding the pathogeneticinvolves a progressive resistance of cells to pro-inflam-
matory mediators, an inactivation of these mediators by role of eosinophils, they produce toxic cationic molecules
that probably participate in tubular damage, and theysoluble molecules, and the production of anti-inflamma-
tory factors [reviewed in 74]. These anti-inflammatory also synthesize pro-inflammatory lipid mediators, which
can contribute to the inflammatory process [reviewed infactors include cytokines such as IL-4, IL-6, IL-10, IL-11,
IL-13, and TGF-, but also by-products of heme catabo- 77]. The prognostic value of renal eosinophilia has not
been carefully studied in patients with drug-inducedlism, neuropeptides such as somatostatin, and products
of arachidonic acid metabolism. Anti-inflammatory ara- AIN, but in patients with acute renal allograft rejection,
renal eosinophilia has been associated with an increasedchidonic acid derivatives include cyclopentenone prosta-
glandins and lipoxygenase derivatives. Cyclopentenone risk of graft loss [78].
Dr. Madias: Do the subsets of lymphocytes identifiedprostaglandins, such as PGD2 or 15 deoxy12-14PGJ2,
exert their anti-inflammatory effects by decreasing the on biopsy have any special significance pathophysiologi-
cally or prognostically?production of nitric oxide, of cytokines such as TNF-,
and of chemoattractants such as monocyte chemoattrac- Dr. Rossert: Different series have studied the per-
centage of CD4 and of CD8 T-cells present withintant protein-1 (MCP-1). Lipoxygenase derivatives, such
as 15-HETE and lipoxins, have anti-inflammatory prop- the interstitial infiltrates. When these series are analyzed
together, the percentages of CD4 and of CD8 T-cellserties that are mediated through an inhibition of the
influx of polymorphonuclear cells and through their abil- vary considerably from one biopsy to the other. While
it was initially suggested that these percentages dependity to bind to PPAR-, which is a member of the nuclear
receptor superfamily, respectively. The repair of tubular on the drug involved, other factors are obviously also
quite important, one of them probably being the timelesions probably occurs through a proliferation of tubu-
lar cells that did not undergo apoptosis or necrosis. As of the biopsy and another one the genetic background
of the patient. It would be tempting to try to associateRobert Safirstein recently highlighted [75], if a pathway
involving mitogen-activated protein kinases (MAPK) the presence of CD8 T-cells with more severe tubular
damage, and the presence of CD4 T-cells with the pres-such as stress-activated protein kinases and p38 MAPK
is antiproliferative and cytoreductive, another MAPK path- ence of higher numbers of monocytes/macrophages, but
so far this is purely speculative. Similarly, to date noway promotes cell survival and proliferation through the
activation of extracellular regulated kinases and the ex- data have suggested that the prognosis of drug-induced
AIN correlates with the subsets of T-cells present withinpression of p21, which is a cyclin-dependent kinase inhib-
itor. This latter pathway is activated by growth factors the interstitial infiltrates, but detailed analyses of infil-
trating T-cells have only been performed in small seriessuch as EGF or TGF-, and it might play an important
role in the repair process of tubular lesions. of renal biopsies.
Dr. Bruno Moulin (Department of Nephrology, Hoˆ-Dr. Madias: Dr. Rossert, can we inhibit CTGF?
Dr. Rossert: Connective tissue growth factor (CTGF) pitaux Universitaires, Strasbourg, France): Je´roˆme, you
mentioned the subset of AIN with granulomas on renalcould be a very important molecule to target to inhibit
TGF--induced fibrotic processes, but so far we do not biopsy. Could you comment on the mechanisms respon-
sible for this type of AIN, and do you know whether ithave a good tool for inhibiting CTGF in vivo. Neverthe-
less, since in vitro cyclic AMP can inhibit the production is more responsive to corticosteroids?
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Dr. Rossert: Granulomatous AINs are secondary to Dr. Mehta: Rifampicin causes AIN when given con-
tinuously or intermittently. Do the mechanisms of AINdelayed-type hypersensitivity reactions, and thus to cell-
mediated immune responses involving TH1 cells. There differ in these two settings? In which case will anti-rifam-
picin antibodies be found, and when do they appear?are no data suggesting that patients with granulomas
have a different prognosis, or that they respond differ- Dr. Rossert: As de Vriese et al recently pointed out,
with few exceptions, rifampicin given continuously isently to treatment with corticosteroids, but once more,
you have to keep in mind that available data are only responsible for AINs that are not associated with anti-
rifampicin antibodies or with extrarenal symptoms suchcoming from small series.
Dr. Ghulam Malik (Security Forces Hospital, Riyadh, as hemolytic anemia or thrombocytopenia [46]. By con-
trast, intermittent regimens are responsible for acuteSaudi Arabia): We know that nonsteroidal anti-inflam-
matory drugs can cause hemodynamically-mediated acute renal failure associated with anti-rifampicin antibodies,
with gastrointestinal symptoms, and in about one-thirdrenal failure, and that they also can cause AIN. How do
we differentiate between these two entities? of the patients with hemolytic anemia and/or thrombo-
cytopenia. Furthermore, in the latter instance, renal biopsyDr. Rossert: Prostaglandins play a significant role in
the maintenance of renal blood flow only in the setting typically shows significant tubular lesions associated with
mild interstitial infiltrates, while in the former, biopsyof decreased actual or effective circulating volume. Thus,
for patients taking an NSAID, hemodynamically-medi- shows mostly substantial inflammatory interstitial infil-
trates. Thus, the mechanisms responsible for acute renalated acute renal failure occurs mostly with an associated
disease such as congestive heart failure, cirrhosis, or failure might not be the same in both cases, and a key
difference could be the presence of anti-rifampicin anti-chronic renal insufficiency, or in the presence of hypo-
volemia. Furthermore, this acute renal failure is not asso- bodies. Since rifampicin appears to bind the I antigen,
which is expressed by red blood cells and by platelets,ciated with proteinuria, hematuria, or extrarenal symp-
toms, but these signs are present in about one-third to but also by tubular epithelial cells, one hypothesis is that
rifampicin binds to tubular cells, and that anti-rifampicintwo-thirds of patients with NSAID-induced AIN. Finally,
although hemodynamically-mediated acute renal failure antibodies participate in the induction of tubular lesions
[46]. Nevertheless, one should keep in mind that patientscan be responsible for acute tubular necrosis when isch-
emia is severe and persistent, most cases improve rapidly can have anti-rifampicin antibodies and no renal lesion.
Regarding the delay between treatment initiation andafter the drug is discontinued, whereas resolution of AIN
is a relatively more prolonged process. Only when renal appearance of anti-rifampicin antibodies, there has been
no systematic study, but a review of the published casesfunction does not improve rapidly after the drug is dis-
continued can one perform a renal biopsy to distinguish shows that the delay between treatment initiation and
occurrence of an acute renal failure is highly variable,between NSAID-induced acute tubular necrosis and
NSAID-induced AIN. ranging from three weeks to about one year [46].
Dr. Malik: When should we perform a renal biopsyDr. Hemant Mehta (Lilavati Hospital and Research
Centre, Bandra Reclamation, Mumbai, India): Are Cox- in patients suspect of having AIN?
Dr. Rossert: The answer to this question depends2-selective inhibitors safe from a renal point of view, and
have they been responsible for AIN? largely on the clinical presentation of the patient. When
acute renal failure occurs one to two weeks after startingDr. Rossert: While Cox-1 is constitutively expressed
in most cells and tissues, Cox-2 is expressed only in a new treatment in a patient with no concomitant disease
that could affect renal function, and the acute renal fail-activated cells. Cox-2-selective inhibitors thus could have
fewer side effects than do conventional NSAIDs, which ure is associated with extrarenal symptoms of hypersen-
sitivity and with eosinophiluria, it is probably not neces-inhibit both Cox-1 and Cox-2. Regarding the kidney,
most available clinical data suggest that Cox-2 is involved sary to perform a renal biopsy. Nevertheless, the clinical
presentation is much less suggestive in most patients, andin the regulation of sodium reabsorption, but its role in
maintaining renal hemodynamics, and thus renal func- it is quite difficult to make an accurate diagnosis without
performing a renal biopsy. In a series of 32 patients, lesstion, is more controversial. Until further studies become
available, clinicians should probably remember the early than 50% of the subjects with clinically suspected AIN
actually had AIN [2]. Most of the others had acute tubu-enthusiasm for sulindac, and assume that Cox-2-selective
inhibitors carry the same risk of impairing renal function lar necrosis, and two had extracapillary glomerulone-
phritis. Our own policy is to perform a renal biopsyas conventional NSAIDs [79]. Regarding the risk of AIN,
I am not aware of any paper describing a case of AIN in patients with clinically suspected AIN before starting
treatment with corticosteroids (that is, when renal func-induced by a Cox-2-selective inhibitor, but once more,
we must be careful because sometimes such rare side tion does not improve within one week after the eliciting
drug is discontinued, or when patients are referred whileeffects are described only when large numbers of patients
have received the drug. the nephropathy has been evolving for more than two
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6. Steblay RW, Rudofsky U: Renal tubular disease and autoantibod-to three weeks), when the drug suspected of having in-
ies against tubular basement membrane induced in guinea pigs.
duced the AIN is important for treating the patient (ei- J Immunol 107:589–594, 1971
7. Rudofsky UH, Pollara B: Studies on the pathogenesis of experi-ther at the time of acute renal failure or in the future),
mental autoimmune renal tubulointerstitial disease in guinea pigs:or when differential diagnoses include renal disease that
Passive transfer of renal lesion by antitubular basement autoanti-
could necessitate a specific treatment. body and non-immune bone-marrow cell to leukocyte-depleted
recipients. Clin Immunol Immunopathol 6:107–114, 1976Dr. Doris M. W. Kinuthia (Aga Ichan Hospital, Nai-
8. Rudofsky UH, Steblay RW, Pollara B: Inhibition of experimen-robi, Kenya): When you decide to give corticosteroids
tal autoimmune renal tubulointerstitial disease in guinea pigs by
to a patient with drug-induced AIN, which regimen do depletion of complement with cobra venom factor. Clin Immunol
Immunopathol 3:396–407, 1975you use?
9. Brown CA, Carey K, Colvin RB: Inhibition of autoimmune tubu-Dr. Rossert: We start with 1 mg/kg/day of prednisone,
lointerstitial nephritis in guinea pigs by heterologous anti-sera con-
and after about one week we rapidly taper the dose to taining anti-idiotype antibodies. J Immunol 123:2102–2107, 1979
10. Neilson EG, Phillips SM: Murine interstitial nephritis. I. Analysisstop the treatment after about one month.
of disease susceptibility and its relationship to pleiomorphic geneDr. Georgi Abraham (Sri Ramachchandra University
products defining both immune-response genes and a restrictive
Hospital, Chennai, India): Angiotensin II might be re- requirement for cytotoxic T cells at H-2K. J Exp Med 155:1075–
1085, 1982sponsible for interstitial fibrosis. Could ACE inhibitors
11. Zakheim B, McCafferty E, Phillips SM, et al: Murine interstitialbe used to retard the progression of interstitial nephritis?
nephritis. II. The adoptive transfer of disease with immune T lym-
Dr. Rossert: Experimental data show that angioten- phocytes produces a phenotypically complex interstitial lesion.
J Immunol 133:234–239, 1984sin II can increase the synthesis of extracellular matrix
12. Ong AC, Fine LG: Tubular-derived growth factors and cytokinesthrough different pathways, and in particular by increas-
in the pathogenesis of tubulointerstitial fibrosis: Implications for
ing the production of TGF-. Nevertheless, the involve- human renal disease progression. Am J Kidney Dis 23:205–209,
1994ment of angiotensin II in the development of interstitial
13. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokinefibrosis probably is quite variable depending on the un-
receptors, and renal disease: from basic science to pathophysiologic
derlying disease. For example, while ACE inhibitors slow and therapeutic studies. J Am Soc Nephrol 11:152–176, 2000
14. Grandaliano G, Gesualdo L, Ranieri E, et al: Monocyte chemo-the progression of chronic renal failure in patients with
tactic peptide-1 expression in acute and chronic human nephritides:glomerulonephritis and proteinuria exceeding 1 g/day, A pathogenetic role in interstitial monocyte recruitment. J Am
no strong data suggest that ACE inhibitors slow the Soc Nephrol 7:906–913, 1996
15. Tang WW, Feng L, Mathison JC, Wilson CB: Cytokine expres-progression of renal failure in patients without protein-
sion, upregulation of intercellular adhesion molecule-1, and leuko-uria. Post-hoc analysis of the AIPRI study even suggests cyte infiltration in experimental tubulointerstitial nephritis. Lab
that patients with nephrosclerosis or interstitial nephritis Invest 70:631–638, 1994
16. Kuroiwa T, Schlimgen R, Illei GG, et al: Distinct T cell/renaldid not benefit from treatment with an ACE inhibitor
tubular epithelial cell interactions define differential chemokine[80]. Thus, today it is difficult to advocate the use of ACE production: Implications for tubulointerstitial injury in chronic glo-
inhibitors in patients with persistently elevated serum merulonephritides. J Immunol 164:3323–3329, 2000
17. Sibalic V, Fan X, Loffing J, Wuthrich RP: Upregulated renalcreatinine after an episode of AIN.
tubular CD44, hyaluronan, and osteopontin in kdkd mice with
interstitial nephritis. Nephrol Dial Transplant 12:1344–1353, 1997
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